Genzyme would like to provide an update to the US Pompe community about the status of the application for Lumizyme™

CRANBURY, N.J., Sept 30, 2009 – – Amicus Therapeutics today announced it plans to initiate a Phase 1 study of

In their second quarter earning statement, Genzyme provided an update on the situation at the Allston manufacturing plant, and the

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items

Dear IPA Affiliate, You will no doubt have heard the wonderful news that MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme. from the Belgian production facility has

Supply Update In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA

Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2 clinical trialA research study that tests new treatments or approaches in people. of its investigational drug

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of Myozyme® (alglucosidase

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has